An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator

Biotechnology and Bioengineering

Volumn 77, Issue 4, 2002, Pages 405-419

  Wootton, David M ^a   Popel, Aleksander S ^a   Alevriadou, B Rita ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrin clot; Fibrinolysis; Fluid shear stress; Mathematical modeling; Tissue type plasminogen activator

Indexed keywords

ADSORPTION; CORRELATION METHODS; FINITE ELEMENT METHOD; SHEAR STRESS; TISSUE;

FIBRINOLYSIS;

BIOMEDICAL ENGINEERING;

ALPHA 2 ANTIPLASMIN; TISSUE PLASMINOGEN ACTIVATOR;

ADSORPTION; ARTERY BLOOD FLOW; ARTICLE; CONFOCAL MICROSCOPY; DIFFUSION; FIBRIN CLOT; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; MATHEMATICAL ANALYSIS; RECANALIZATION; SHEAR STRESS; THROMBUS;

BLOOD FLOW VELOCITY; FIBRIN; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMODYNAMIC PROCESSES; HUMANS; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037083201     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.10127     Document Type: Article

References (36)

1. Mechanisms by which thrombolytic therapy results in nonuniform lysis and residual thrombus after reperfusion
2. Enzyme-mediated proteolysis of fibrous biopolymers: Dissolution front movement in fibrin or collagen under conditions of diffusive or convective transport
3. Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi
4. The effect of flow and mass transport in thrombogenesis
5. Native fibrin gel networks observed by 3d microscopy, permeation and turbidity
6. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy
7. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: Dynamic and structural approaches by confocal microscopy
8. Inner clot diffusion and permeation during fibrinolysis
9. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry
10. Molecular assembly of plasminogen and tissue-type plasminogen activator on an evolving fibrin surface
11. Lewis A. Conner memorial lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
12. Determinants of coronary blood flow after thrombolytic administration. TIMI study group. Thrombolysis in myocardial infarction
13. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow
14. Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro fibrin clot: Evidence for a key role of endothelial cells in thrombolytic resistance
15. Boundary conditions at the cartilage-synovial fluid interface for joint lubrication and theoretical verifications
16. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots
17. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products
18. Flow rate-modulated dissolution of fibrin with clot-embedded and circulating proteases
19. The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity
20. Pressure drop due to the entrance region in ducts of arbitrary cross section
21. Properties of thrombolytic agents in vitro using a perfusion circuit attaining shear stress at physiological levels
22. Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transition
23. Fibrinolysis
24. Type 1 plasminogen activator inhibitor binds to fibrin via vitronectin
25. Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis. Study with confocal microscopy
26. Superficial accumulation of plasminogen during plasma clot lysis
27. The effect of flow on lysis of plasma clots in a plasma environment
28. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus thrombolysis for occluded coronary arteries in patients with acute myocardial infarction study investigators
29. Progressive cross-linking of fibrin gamma chains increases resistance to fibrinolysis
30. Pharmacodynamics of tissue-type plasminogen activator characterized by computer-assisted simulation
31. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions
32. Tissue plasminogen activator (tpa) inhibits plasmin degradation of fibrin. A mechanism that slows tpa-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen
33. Flow characteristics in models of arterial stenosis - I. Steady flow
34. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro
35. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator
36. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: Mathematical modelling of two idealised cases